Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer

Keyphrases

• SNP 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Genetic Variation 100%
• Taxanes 100%
• Outcome Prediction 100%
• Pathway Genes 100%
• Platinating Agents 100%
• Paclitaxel 40%
• Drug Transporters 40%
• Neutropenia 40%
• Performance Status 40%
• Hematotoxicity 40%
• ATP Binding Cassette Subfamily B Member 1 (ABCB1) 40%
• Tolerability 20%
• Response Predictors 20%
• Non-small Cell Lung Cancer (NSCLC) 20%
• Malignancy 20%
• Carboplatin 20%
• Chemotherapy 20%
• Therapeutic Strategies 20%
• Genomic DNA (gDNA) 20%
• Thrombocytopenia 20%
• Adult Male 20%
• Clinical Response 20%
• ABCG2 20%
• Genetic Profile 20%
• Cancer Mortality 20%
• Male Patients 20%
• Cancer Causes 20%
• Clinical Factors 20%
• Nausea 20%
• Multivariate Model 20%
• Progression-free Survival 20%
• DNA Repair Genes 20%
• Sensory Neuropathy 20%
• Univariate Model 20%
• Pharmacodynamic Biomarker 20%
• NQO1 20%
• Clinical Toxicity 20%
• ABCC1 20%
• ERCC4 20%
• DNA Samples 20%
• Lung Carcinoma 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Taxane 100%
• Non Small Cell Lung Cancer 100%
• Paclitaxel 50%
• Neutropenia 50%
• Tolerability 25%
• Prospective Study 25%
• Chemotherapy 25%
• Pharmacogenetics 25%
• ABCG2 25%
• Cancer Mortality 25%
• Nausea 25%
• Progression Free Survival 25%
• Lung Carcinoma 25%
• Genomic DNA 25%
• Sensory Neuropathy 25%
• ABCC1 25%
• Thrombocytopenia 25%
• Carboplatin 25%

Biochemistry, Genetics and Molecular Biology

• Single Nucleotide Polymorphism 100%
• Genetic Variation 100%
• Candidate Gene 40%
• Genetics 20%
• Prospective Study 20%
• ABCC1 20%
• Pharmacogenetics 20%
• DNA Repair 20%
• Cancer Mortality 20%
• Progression Free Survival 20%
• Thrombocytopenia 20%
• ABCG2 20%